DiaMedica Therapeutics - DMAC Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DMAC shares.
View DMAC analyst ratings or view top-rated stocks.

3 brokerages have issued 1-year price targets for DiaMedica Therapeutics' stock. Their DMAC share price forecasts range from $8.00 to $12.00. On average, they expect the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 733.3% from the stock's current price.
View analysts price targets for DMAC or view top-rated stocks among Wall Street analysts.

DiaMedica Therapeutics' stock was trading at $3.73 at the beginning of the year. Since then, DMAC shares have decreased by 67.8% and is now trading at $1.20.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our DMAC earnings forecast.

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) issued its quarterly earnings results on Wednesday, August, 10th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.03.

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Pfizer (PFE), Vaxart (VXRT), Aldeyra Therapeutics (ALDX), Capricor Therapeutics (CAPR), Oncolytics Biotech (ONCY), Sesen Bio (SESN) and Sorrento Therapeutics (SRNE).

(DMAC) raised $18 million in an initial public offering on Friday, December 7th 2018. The company issued 4,000,000 shares at a price of $4.00-$5.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.

DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC."

DiaMedica Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Dietrich John Pauls, Harry W Alcorn Jr, Koch Thomas Von, Randall Michael Giuffre, Richard D Pilnik and Scott Kellen.
View institutional ownership trends.

Shares of DMAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DMAC stock can currently be purchased for approximately $1.20.

DiaMedica Therapeutics (NASDAQ:DMAC) has a market capitalization of $31.73 million. The company earns $-13,590,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis.

DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The official website for the company is www.diamedica.com. The company can be reached via phone at (763) 312-6755 or via email at skellen@diamedica.com.